4.5 Article

Clear Cell Melanoma A Cutaneous Clear Cell Malignancy

期刊

ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
卷 138, 期 10, 页码 1328-1336

出版社

COLL AMER PATHOLOGISTS
DOI: 10.5858/arpa.2014-0307-CC

关键词

-

资金

  1. Dermatopathology Research Career Development Award of the Dermatology Foundation

向作者/读者索取更多资源

Clear cell melanoma is a rare clear cell malignancy. Accurate diagnosis of clear cell melanoma requires integration of immunohistochemical and morphologic findings, with molecular studies to rule out clear cell sarcoma. The differential diagnosis includes melanoma, carcinoma, perivascular epithelioid cell tumor, and epidermotropic clear cell sarcoma. We use a case of a lesion on the helix of an 86-year-old man as an example. Histologic examination revealed an ulcerated clear cell malignant tumor. Tumor cell cytoplasm contained periodic acid-Schiff-positive, diastase-sensitive glycogen. Tumor cells showed positive labeling for S100, HMB-45, and Melan-A, and negative labeling for cytokeratins, p63, and smooth muscle actin. Molecular studies demonstrated BRAF V600E mutation, copy gains at the 6p25 (RREB1) and 11q13 (CCND1) loci, and absence of EWSR1-ATF1 fusion. These findings supported a diagnosis of clear cell melanoma. The rare pure clear cell morphology occurs due to accumulation of intracytoplasmic glycogen. We review the differential diagnosis of clear cell melanoma and describe the utility of immunohistochemical and molecular studies in confirming this diagnosis.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Review Cell Biology

Molecular pathology of skin adnexal tumours

Jaclyn M. Plotzke, David J. Adams, Paul W. Harms

Summary: Recent discoveries have revealed diverse oncogenic drivers and tumour suppressor alterations in adnexal tumours, implicating various pathways and identifying novel markers.

HISTOPATHOLOGY (2022)

Article Dermatology

Viral Status Predicts the Patterns of Genome Methylation and Decitabine Response in Merkel Cell Carcinoma

Paul W. Harms, Monique E. Verhaegen, Josh N. Vo, Jean C. Tien, Drew Pratt, Fengyun Su, Saravana M. Dhanasekaran, Xuhong Cao, Doris Mangelberger, Julia VanGoor, Jae Eun Choi, Vincent T. Ma, Andrzej A. Dlugosz, Arul M. Chinnaiyan

Summary: This study investigated DNA methylation in MCC and found similar patterns to other cancer types. The hypomethylating agent decitabine has therapeutic effects on antigen-presenting mechanisms and shows differential effects on MCC cells with different viral status.

JOURNAL OF INVESTIGATIVE DERMATOLOGY (2022)

Review Cell Biology

Molecular testing for melanocytic tumors: a practical update

Aleodor A. Andea

Summary: The work-up of melanocytic tumors has evolved significantly in recent years due to the rapid development of molecular assays. This article provides an updated overview of the major ancillary tests used in clinical practice, which can help pathologists in the diagnosis and classification of melanocytic tumors, as well as in predicting prognosis and response to systemic therapy in melanoma.

HISTOPATHOLOGY (2022)

Article Pathology

Genomic evidence suggests that cutaneous neuroendocrine carcinomas can arise from squamous dysplastic precursors

Paul W. Harms, Monique E. Verhaegen, Kevin Hu, Steven M. Hrycaj, May P. Chan, Chia-Jen Liu, Marina Grachtchouk, Rajiv M. Patel, Aaron M. Udager, Andrzej A. Dlugosz

Summary: MCC and SCCIS show significant overlap in gene mutations, with no unique gene mutations found in all cases of MCC. Transcriptome analysis reveals large differences in gene expression between MCC and SCCIS, including epidermal markers and immune genes. Immunohistochemistry studies show increased expression of SOX2 in the MCC component.

MODERN PATHOLOGY (2022)

Article Dermatology

PRAME expression is similar in scar and desmoplastic melanoma

Jaclyn M. Plotzke, Nicholas A. Zoumberos, Steven M. Hrycaj, Paul W. Harms, Scott C. Bresler, May P. Chan

JOURNAL OF CUTANEOUS PATHOLOGY (2022)

Article Cell Biology

PRAME expression in spindle cell melanoma, malignant peripheral nerve sheath tumour, and other cutaneous sarcomatoid neoplasms: a comparative analysis

Steven M. Hrycaj, Julianne M. Szczepanski, Lili Zhao, Javed Siddiqui, Dafydd G. Thomas, David R. Lucas, Rajiv M. Patel, Paul W. Harms, Scott C. Bresler, May P. Chan

Summary: PRAME immunostain can aid in distinguishing spindle cell melanoma from other sarcomatoid neoplasms, but its use should be as part of an immunohistochemical panel rather than a standalone diagnostic marker.

HISTOPATHOLOGY (2022)

Letter Dermatology

Comment on An Epidemiologic Analysis of Melanoma Overdiagnosis in the United States, 1975-2017

Paul W. Harms, May P. Chan, Scott C. Bresler, Aleodor A. Andea, Alexandra C. Hristov, Douglas R. Fullen, Rajiv M. Patel, Lori Lowe

JOURNAL OF INVESTIGATIVE DERMATOLOGY (2022)

Article Pathology

Molecular testing in melanoma for the surgical pathologist

Aleodor A. Andea

Summary: The diagnostic work-up of melanocytic tumors has been revolutionized in recent years with the advent of molecular assays. This review gives an overview of the major molecular tests used in clinical practice, including predicting therapy response, prognosis, tumor classification, and differential diagnosis.

PATHOLOGY (2022)

Article Pathology

Expression of SATB2 in primary cutaneous sarcomatoid neoplasms: a potential diagnostic pitfall

Julianne M. Szczepanski, Javed Siddiqui, Rajiv M. Patel, Paul W. Harms, Steven M. Hrycaj, May P. Chan

Summary: SATB2 can serve as an immunohistochemical marker for osteoblastic differentiation. The expression of SATB2 was evaluated in different cutaneous sarcomatoid neoplasms, and it was found to be common in these tumors except for atypical fibroxanthomas. Strong staining and a high-positive h-score can improve the specificity of SATB2 in differentiating these tumors from osteosarcoma.

PATHOLOGY (2023)

Article Dermatology

CD30 expression in cutaneous B-cell lymphomas

Olabisi Afolayan-Oloye, Lili Zhao, Trilokraj Tejasvi, May P. Chan, Paul W. Harms, Douglas R. Fullen, Ryan A. Wilcox, Alexandra C. Hristov

Summary: This study investigated the expression of CD30 in cutaneous B-cell lymphomas (CBCLs) and correlated it with clinicopathological features. The results showed that CD30 was expressed in 35% of CBCL cases, with varying intensity and extent. CD30 expression was most common in primary cutaneous follicle center lymphoma (PCFCL) and associated with favorable clinical features. In cases with strong and diffuse expression, CD30 could potentially be a therapeutic target.

JOURNAL OF CUTANEOUS PATHOLOGY (2023)

Article Multidisciplinary Sciences

Single cell and spatial sequencing define processes by which keratinocytes and fibroblasts amplify inflammatory responses in psoriasis

Feiyang Ma, Olesya Plazyo, Allison C. C. Billi, Lam C. C. Tsoi, Xianying Xing, Rachael Wasikowski, Mehrnaz Gharaee-Kermani, Grace Hile, Yanyun Jiang, Paul W. W. Harms, Enze Xing, Joseph Kirma, Jingyue Xi, Jer-En Hsu, Mrinal K. K. Sarkar, Yutein Chung, Jeremy Di Domizio, Michel Gilliet, Nicole L. L. Ward, Emanual Maverakis, Eynav Klechevsky, John J. J. Voorhees, James T. T. Elder, Jun Hee Lee, J. Michelle Kahlenberg, Matteo Pellegrini, Robert L. L. Modlin, Johann E. E. Gudjonsson

Summary: Single cell and spatial transcriptomics can be used to investigate changes in Psoriasis and other inflammatory skin diseases during severity stages. The authors compared different inflammatory skin diseases and found differences in immune cells and inflammatory markers, with a particular focus on keratinocytes and fibroblasts. The study revealed IL-36 dependent amplification of IL-17A and TNF inflammatory responses in psoriasis, occurring within the supraspinous layer of the skin. They also identified a subset of SFRP2(+) fibroblasts in psoriasis that contribute to immune network amplification through a pro-inflammatory state transition.

NATURE COMMUNICATIONS (2023)

Article Dermatology

MAP2K1-mutated melanocytic tumors have reproducible histopathologic features and share similarities with melanocytic tumors with BRAF V600E mutations

Ahmed K. Alomari, Paul W. Harms, Aleodor A. Andea, Simon J. Warren

Summary: This study investigates the characteristics and features of melanocytic tumors driven by MAP2K1 in-frame deletions. The findings suggest that these tumors share similarities with Spitz tumors but are better classified along the conventional pathway. Furthermore, they have a high mutational burden and show ultraviolet radiation features, similar to tumors with BRAF V600E mutations.

JOURNAL OF CUTANEOUS PATHOLOGY (2023)

Review Pathology

Multiplex Immunohistochemistry and Immunofluorescence: A Practical Update for Pathologists

Paul W. Harms, Timothy L. Frankel, Myrto Moutafi, Arvind Rao, David L. Rimm, Janis M. Taube, Dafydd Thomas, May P. Chan, Liron Pantanowitz

Summary: Our understanding of human disease has evolved greatly in recent decades, particularly in the areas of immunology and cancer treatment. Advances in digital pathology have opened new avenues for studying the tumor microenvironment. Traditional tissue-based evaluations are limited in their ability to analyze complex quantitative data and multiple biomarkers, making multiplex staining techniques a promising alternative.

MODERN PATHOLOGY (2023)

Article Medicine, Research & Experimental

Direct cellular reprogramming enables development of viral T antigen-driven Merkel cell carcinoma in mice

Monique E. Verhaegen, Paul W. Harms, Julia J. Van Goor, Jacob Arche, Matthew T. Patrick, Dawn Wilbert, Haley Zabawa, Marina Grachtchouk, Chia-Jen Liu, Kevin Hu, Michael C. Kelly, Ping Chen, Thomas L. Saunders, Stephan Weidinger, Li-Jyun Syu, John S. Runge, Johann E. Gudjonsson, Sunny Y. Wong, Isaac Brownell, Marcin Cieslik, Aaron M. Udager, Arul M. Chinnaiyan, Lam C. Tsoi, Andrzej A. Dlugosz

Summary: Merkel cell carcinoma (MCC) is an aggressive skin cancer that expresses specific genes similar to skin-resident Merkel cells. Researchers have used ATOH1 to induce MCC development in mice by cellular reprogramming. By conditionally expressing MCPyV TAgs and ATOH1 in mouse epidermal cells, they were able to generate MCC-like tumor cells from hair follicles. The study confirmed the similarity between mouse and human MCCs and revealed that loss of p53 is necessary for the progression of MCC in this mouse model.

JOURNAL OF CLINICAL INVESTIGATION (2022)

暂无数据